Current Report Filing (8-k)
January 06 2023 - 3:05PM
Edgar (US Regulatory)
0001266806
false
0001266806
2023-01-06
2023-01-06
iso4217:USD
xbrli:shares
iso4217:USD
xbrli:shares
UNITED
STATES
SECURITIES
AND EXCHANGE COMMISSION
WASHINGTON,
D.C. 20549
FORM
8-K
CURRENT
REPORT
Pursuant
to Section 13 OR 15(d) of The Securities Exchange Act of 1934
Date
of Report (Date of earliest event reported): January 6, 2023
VIVANI
MEDICAL, INC.
(Exact
name of registrant as specified in its charter)
California |
|
001-36747 |
|
02-0692322 |
(State
or other jurisdiction of
incorporation) |
|
(Commission
File
Number) |
|
(IRS
Employer
Identification
No.) |
5858
Horton Street, Suite 280
Emeryville,
California |
|
94608 |
(Address
of principal executive offices) |
(Zip
Code) |
Registrant’s
telephone number, including area code: (818) 833-5000
(Former
name or former address, if changed since last report.)
Check
the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant
under any of the following provisions:
☐ |
Written communications
pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
☐ |
Soliciting material
pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) |
☐ |
Pre-commencement communications
pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) |
☐ |
Pre-commencement communications
pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
Securities
registered pursuant to Section 12(b) of the Act:
Title
of each class |
|
Trading
Symbol(s) |
|
Name
of each exchange on which registered |
Common Stock |
|
VANI |
|
Nasdaq Capital Market |
Indicate
by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405
of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging
growth company ☐
If
an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for
complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Item 7.01. Regulation
FD Disclosure
Vivani
Medical, Inc. (the “Company”) from time to time presents and/or distributes to the investment community at various
industry and other conferences slide presentations to provide updates and summaries of its business. These slides are attached
to this Current Report on Form 8-K as Exhibit 99.1 and are incorporated by reference herein. The Company is also posting to the
“Investors” portion of its website a copy of its current corporate slide presentation. The
slides speak as of the date of this Current Report on Form 8-K. While the Company may
elect to update the slides in the future or reflect events and circumstances occurring or existing after the date of this Current
Report on Form 8-K, the Company specifically disclaims any obligation to do
so. The information contained in this Item 7.01 and Exhibit 99.1 hereto shall not be deemed “filed” for
purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or incorporated by
reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as shall be expressly set forth
by reference in such a filing.
Item
9.01 Financial Statements and Exhibits.
(d)
Exhibits.
SIGNATURE
Pursuant
to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf
by the undersigned hereunto duly authorized.
|
VIVANI
MEDICAL, INC. |
|
|
|
Date: January 6,
2023 |
By: |
/s/
Donald Dwyer |
|
|
Donald
Dwyer |
|
|
Chief
Business Officer |
Second Sight Medical Pro... (NASDAQ:EYES)
Historical Stock Chart
From Sep 2024 to Oct 2024
Second Sight Medical Pro... (NASDAQ:EYES)
Historical Stock Chart
From Oct 2023 to Oct 2024
Real-Time news about Second Sight Medical Products Inc (NASDAQ): 0 recent articles
More Vivani Medical, Inc. News Articles